BIT Capital GmbH Acquires 731 Shares of argenx SE (NASDAQ:ARGX)

BIT Capital GmbH boosted its stake in argenx SE (NASDAQ:ARGX) by 22.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,032 shares of the company’s stock after acquiring an additional 731 shares during the period. BIT Capital GmbH’s holdings in argenx were worth $2,480,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ARGX. Whipplewood Advisors LLC bought a new stake in shares of argenx during the 4th quarter valued at about $37,000. Global Retirement Partners LLC lifted its holdings in argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the period. Jones Financial Companies Lllp boosted its position in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after acquiring an additional 61 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of argenx by 78.6% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock worth $46,000 after acquiring an additional 33 shares during the period. Finally, Farther Finance Advisors LLC raised its position in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after acquiring an additional 21 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Trading Down 3.6 %

ARGX opened at $583.66 on Thursday. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The company has a market cap of $35.46 billion, a price-to-earnings ratio of -663.25 and a beta of 0.59. The company’s 50 day moving average is $630.61 and its 200 day moving average is $601.00.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. As a group, analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ARGX shares. JMP Securities lifted their price target on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 14th. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Wedbush reiterated an “outperform” rating and issued a $655.00 price target on shares of argenx in a research note on Tuesday, December 3rd. Guggenheim boosted their price objective on shares of argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Finally, Piper Sandler raised their target price on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $687.00.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.